Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 versus physician's choice in third-line or later advanced/metastatic gastroesophageal adenocarcinoma
2023-505423-31-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival. Planned start Aug 2024; status: authorised.
02
Drugs
sacituzumab tirumotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-505423-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505423-31-00.